TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01875250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F (Fowlpox)/TRICOM
Description: A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V (Vaccinia)/TRICOM
Description: A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide (Xtandi)
Description: An androgen receptor inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide (Xtandi)
Description: An androgen receptor inhibitor.
Study: NCT02139696

Intervention type: RADIATION
Intervention: PET and MRI
Description: Patients will be imaged using PET and MRI at baseline, and twice during treatment
Study: NCT02273986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Study: NCT02077426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional Specific Training (RSTS)
Description: The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
Study: NCT00867867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Description: 9.3 mg once per day, 6 days per week, for 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric pyrophosphate
Description: 9.3 mg once per day, 6 days per week, for 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9.3 mg once per day, 6 days per week, for 9 months
Study: NCT01875848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: partial opioid agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid dose escalation
Description: up to 25% increase in patient's current opioid dose
Study: NCT02952209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft
Study: NCT03720236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant bed preparation protocol
Description: This is the first surgical phase, we prepare the implant bed by using different increasing size drills.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant bed preparation protocol
Description: This is the first surgical phase, we prepare the implant bed by using different increasing size drills.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant loading
Description: This is the second phase, based on prosthetic procedures, to design the crown over the dental implant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant loading
Description: This is the second phase, based on prosthetic procedures, to design the crown over the dental implant
Study: NCT00482729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate (+) metformin hydrochloride
Description: sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
Study: NCT02328963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus : 0.75 bid, targeted to 3-8 ng/ml~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolic acid
Description: Mycophenolic acid :~1080 mg bid for one month, then 720 mg bid~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg
Study: NCT00997321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
Study: NCT01645423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium Tablets, 80 mg
Description: Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Study: NCT01758822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No endotracheal suction
Description: Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
Study: NCT03064321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia Intervention
Description: The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.

Intervention type: OTHER
Group type: OTHER
Intervention: Information Control
Description: Information on websites that are general health promoting
Study: NCT02726919

Intervention type: DRUG
Group type: OTHER
Intervention: Clobazam
Description: Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
Study: NCT03601546

Intervention type: OTHER
Intervention: Clinical examination
Description: Blood test and patient interview as for standard patient care
Study: NCT01057381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.75 mcg/kg
Description: Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 50 mcg/kg
Description: Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 100 mcg/kg
Description: Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1 mcg/kg
Description: Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
Study: NCT00986453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Description: The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Electrosurgery with scalpel
Description: Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
Study: NCT01148641

Intervention type: DIETARY_SUPPLEMENT
Intervention: LNS
Description: Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days (crossover design) and thereafter, 20 g per day for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Intervention: LNS
Description: Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days (crossover design) and thereafter, 20 g per day for 14 days.
Study: NCT02113176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Study: NCT03153618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VALIDATE system
Description: Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
Study: NCT04948957

Intervention type: DRUG
Intervention: Esmolol

Intervention type: DRUG
Intervention: Nitroglycerin
Study: NCT06132620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoston
Description: Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingxin Zishen Decoction
Description: Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
Study: NCT02980302

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cutaneous biopsy
Description: Under local anesthesia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cutaneous biopsy
Description: Under local anesthesia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cutaneous biopsy
Description: Under local anesthesia
Study: NCT00997321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
Study: NCT05178251

Intervention type: PROCEDURE
Intervention: appendectomy
Description: appendectomy for acute appendicitis

Intervention type: PROCEDURE
Intervention: appendectomy
Description: appendectomy for acute appendicitis
Study: NCT00633126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftaroline
Description: Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
Study: NCT03804398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compliance guided an optimal Positive End-Expiratory Pressure
Description: The study groups received an alveolar recruitment maneuver(increase inspiratory pressure to 30cmH2O for 10s) at the 10min after one-lung ventilation. After the alveolar recruitment maneuver,the study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained.
Study: NCT05360355

Intervention type: PROCEDURE
Intervention: total face reconstruction surgery and intraoperative indocyanine green angiography
Description: Patients with total facial scarring following burn injury were treated with monoblock pre-expanded prefabricated flaps for total face restoration. The opening of nostrils, oral and palpebral orifices, together with organ fabrication, were conducted under the guidance of intraoperative ICGA for hemodynamic evaluation.
Study: NCT04392336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trust/Respect feedback
Description: This feedback includes information on the level of trust/respect that a consumer has for their clinician in addition to symptom feedback.
Study: NCT05663736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: DPP-4 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride
Study: NCT03985748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAN
Description: Inhaled bronchodilators will be delivered using an AeroEclipse® II Breath Actuated Nebuliz (BAN)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SN
Description: Inhaled bronchodilators will be delivered using a Standard Nebulizer (SN)
Study: NCT03943953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Therapy Guides
Description: We have developed seven self-guided information and therapy guides (ITGs), for people with facial palsy and/or their friends or relatives. We have written these guides by drawing on interventions with a strong evidence-base in other populations, such as cognitive behavioural therapy, social skills training and acceptance and commitment therapy:~1. Facial palsy: Coping with the early stages.~2. Facial palsy: Coping with comments, questions and staring.~3. Facial palsy: Communicating with confidence.~4. Facial palsy: Managing anxiety.~5. Facial palsy: Managing your mood.~6. Facial palsy: Building your self-esteem.~7. Facial palsy: Advice for friends, family and partners.
Study: NCT01835613

Intervention type: OTHER
Group type: OTHER
Intervention: Biomarkers Measures
Description: At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.
Study: NCT03832439

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Lactobacillus rhamnosus GG 10 billion cells and microcrystalline cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: Placebo
Study: NCT04786132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-motor training
Description: A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor training
Description: A training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups.
Study: NCT00505232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-90 Ibritumomab tiuxetan
Description: Study Design~The present study will be split into two cohorts:~1. Patients younger than 60 years who will receive 8 chemotherapy cycles~2. Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) \[0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets \< 100,000/µl\] will be administered 8 to 12 weeks after last chemotherapy.
Study: NCT03629041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Patch
Description: At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Patch with no microneedles
Description: At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
Study: NCT02230878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 5 mg
Description: Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 10 mg
Description: Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 20 mg
Description: Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 40 mg
Description: Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo from Day 1 up to Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo from Day 1 up to Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo from Day 1 up to Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo from Day 1 up to Day 10.
Study: NCT02815293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-195263
Description: 1 drop of AGN-195263 will be instilled in each eye twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
Study: NCT03508765

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Structural Image
Description: Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional Image
Description: Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digit Span subtest
Description: Evaluates auditory attention and working memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Test of Attention
Description: Assesses selective auditory attention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trail Making Test (Parts A & B)
Description: Assesses visual scanning, graphomotor speed, and setshifting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Consonant Trigrams Test
Description: Assesses attention and susceptibility to interference

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled Oral Word Association Test
Description: A timed test of verbal fluency.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hopkins Verbal Learning Test-Revised
Description: The HVLT-R is a test of verbal learning and recall.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Center for Epidemiological Study-Depression
Description: assesses perceived depression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4
Description: A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.
Study: NCT00511342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG-EE
Description: Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
Study: NCT02370017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANKL(Ex vivo-expanded NK cell enriched lymphocytes)
Description: add ANKL in 3rd and 4th course in case of stable response after two initial courses
Study: NCT03201952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ileostomy administration of 300mg UDCA once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ileostomy administration of 300mg UDCA once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Ileostomy administration of 5cc saline placebo once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Ileostomy administration of 5cc saline placebo once
Study: NCT05065996

Intervention type: DIAGNOSTIC_TEST
Intervention: Aortic MRI + 4D flow MRI
Description: Together with routine aortic MRI specific 4D flow MRI sequence will be done.

Intervention type: DIAGNOSTIC_TEST
Intervention: Aortic MRI + 4D flow MRI
Description: Together with routine aortic MRI specific 4D flow MRI sequence will be done.

Intervention type: DIAGNOSTIC_TEST
Intervention: Aortic MRI + 4D flow MRI
Description: Together with routine aortic MRI specific 4D flow MRI sequence will be done.
Study: NCT00897325

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03585322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1387 for Injection
Description: Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
Study: NCT02432040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, made to look like the interventional drug